Tiziana Life Sciences #TILS Announces Proposed U.S. Public Offering of ADSs February 17, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York and London, February 17, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the “Company” or “Tiziana”), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces the commencement of an underwritten public offering in the United States of  American Depositary Shares (“ADSs”), representing ordinary shares of nominal value £0.03 each in the capital of the…

Continue reading

Tiziana Life Sciences #TILS – Change to ADS ratio October 30, 2019 – Posted in: Tiziana Life Sciences (TILS)

London, 30 October 2019 – Tiziana Life Sciences plc (“Tiziana”, AIM: TILS, NASDAQ: TLSA), announces a ratio change to its sponsored Level I American Depositary Receipt (“ADR”) programme. The former ratio of ten (10) ordinary shares to one (1) American Depositary Share (“ADS”) has been changed to five (5) ordinary shares per one (1) ADS effective on 29 October 2019. There will be no change to the underlying ordinary shares. ADR record date: 21 October 2019…

Continue reading